Investors parsing Bayer’s second-quarter numbers are confronting a company that is simultaneously healing and straining. The German life-science group delivered another quarter of modest top-line growth, yet the figures beneath the surface tell a more layered story — one where operational momentum in agriculture and pharma is being offset by rising financing costs and a balance sheet that keeps expanding.
Group revenue reached €10.872 billion in the second quarter of 2026, up 2.2 percent on a currency- and portfolio-adjusted basis. Adjusted EBITDA advanced 1.9 percent to €2.144 billion, extending the gradual recovery trend of recent quarters. But the optics shift sharply at the per-share level: Core earnings per share tumbled 16.7 percent year-on-year to €0.95, a gap the company attributes to higher financing expenses and special items, though management declined to elaborate.
That divergence frames the central tension for shareholders. The underlying businesses are contributing, but below the operating line, the drag is unmistakable.
Crop Science Leads, Pharma Surprises
The strongest operational push came from Crop Science, where adjusted earnings jumped 30.2 percent — a notable inflection after years of pricing pressure in the agricultural segment. The division’s resilience was underscored by continued market leadership in corn herbicides and seeds, positioning it as a cash-flow anchor even if it no longer serves as the primary growth narrative.
Pharma, meanwhile, delivered its own set of surprises. Nubeqa posted first-half sales growth of 61 percent, while Kerendia surged 84 percent. The newer launches Beyonttra and Lynkuet are also progressing, according to the company, and together these products are expected to help close the revenue gap left by patent expiries on older blockbusters — a structural challenge that has shadowed the group for years.
Kerendia’s trajectory deserves particular scrutiny. The drug generated €329 million in second-quarter sales, up 80 percent from the prior-year period, and Bayer reaffirmed its target of surpassing the €1 billion mark for the full year. The question is whether that growth rate can persist as the comparison base expands — an 80 percent jump from a low starting point is far easier to achieve than sustained momentum in absolute terms.
Regulatory Momentum in Asia
The pharma story gained fresh validation in recent weeks through a cluster of regulatory developments. In Japan, Bayer filed for approval of Kerendia in non-diabetic chronic kidney disease, backed by positive Phase III data from the FIND-CKD study. Days earlier, the company had already secured Japanese market authorization for Hyrnuo (Sevabertinib) in HER2-mutated lung cancer.
Should investors sell immediately? Or is it worth buying Bayer?
These wins matter because they shift the valuation debate away from pure glyphosate relief and toward whether the pharma pipeline can genuinely replace the revenue hole left by patent cliffs. The stock’s current position — roughly 18 percent above its 200-day average of €41.29 — suggests the market is already pricing in some of this transition.
The Legal Calendar Still Looms
On the litigation front, the picture is improving but far from settled. A US appeals court in the Eighth Circuit dismissed an objection to the $7.25 billion Roundup settlement, leaving jurisdiction with a Missouri court. That follows the Supreme Court’s early-July ruling in Bayer’s favor regarding cancer warning labels on glyphosate products.
The next concrete milestone is the September 14 hearing on final approval of the class settlement. A favorable outcome could free up capital discipline and refocus investor attention on the pharma story. But the hearing remains a procedural step, not a guaranteed victory — further objections or delays could easily extend the legal uncertainty that has weighed on the shares for years.
Balance Sheet Pressures Persist
Financing remains a mixed picture. Net financial debt rose to €33.647 billion as of June 30, up 3.5 percent from the end of the first quarter. In mid-July, Bayer successfully placed $5 billion in bonds with maturities ranging from five to thirty years, with demand significantly exceeding supply — a sign that credit markets remain receptive even as leverage stays elevated.
The company confirmed its full-year 2026 guidance alongside the quarterly release, pointing to progress on legal risks, organizational restructuring, and the innovation pipeline. Management’s message is consistent: despite ongoing litigation burdens, the self-imposed targets remain within reach.
Market Response and the Road Ahead
The equity market’s reaction has been measured. Shares closed Friday at €48.66, up 0.4 percent on the day. Over the past 30 days, the gain totals 2.5 percent, while the year-to-date advance stands at 31 percent. The stock remains 9.7 percent below its 52-week high of €53.86, reached in early July, with the relative strength index at a neutral 53.5.
The combination of solid operational growth, a declining per-share earnings figure, and rising debt is likely to keep the shares range-bound in the near term. The decisive variables are whether Crop Science and the newer pharma products can sustain their momentum — and whether the September 14 hearing delivers the legal clarity that would allow the market to fully embrace the pharma transformation story. Until then, Bayer remains a balancing act between legal relief and pipeline promise.
Ad
Bayer Stock: Buy or Sell?! New Bayer Analysis from August 29 delivers the answer:
The latest Bayer figures speak for themselves: Urgent action needed for Bayer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 29.
Bayer: Buy or sell? Read more here...
